Aurinia Pharmaceuticals Inc
AUPH
NASDAQ
Biotechnology
$15.47
USD
+0.29 (+1.91%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.01B
Volume 826.3K
Revenue
$311.51M
TTM
+19.8%
YoY
Gross Margin
90%
TTM
+0.9%
YoY
Net Income
$314.11M
TTM
+418.0%
YoY
Operating Cash Flow
$175.24M
TTM
+89.1%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 70.0 | 73.5 | 77.1 | 77.7 | 83.2 |
YoY Growth | +22.4% | +8.4% | +28.8% | +24.4% | +18.9% |
Cost of Revenue | 7.1 | 8.2 | 8.8 | 6.5 | 6.6 |
Gross Profit | 62.9 | 65.3 | 68.3 | 71.2 | 76.7 |
Selling, General & Administrative | 26.0 | 26.2 | 29.3 | 22.0 | 23.5 |
Other Operating Expenses | 9.4 | 0.0 | 9.5 | 0.3 | -6.2 |
Total Operating Expenses | 42.8 | 34.6 | 49.7 | 29.8 | 30.3 |
Operating Income | 20.1 | 30.7 | 18.6 | 41.4 | 46.3 |
EBITDA | 25.1 | 35.5 | 23.5 | 46.2 | 51.2 |
Other Income / Expense | 0.0 | -0.9 | 14.6 | 0.0 | 0.0 |
Total Other Income / Expense | 2.1 | 1.3 | 17.1 | 2.5 | 2.4 |
Income Before Income Taxes | 22.2 | 32.0 | 35.7 | 43.9 | 48.8 |
Income Taxes | 0.6 | 0.4 | -175.1 | 9.6 | 11.4 |
Net Income | 21.5 | 31.6 | 210.8 | 34.4 | 37.4 |
Consolidated Net Income / Loss | 21.5 | 31.6 | 210.8 | 34.4 | 37.4 |
Net Income Attributable to Common Shareholders | 21.5 | 31.6 | 210.8 | 34.4 | 37.4 |
Basic EPS | $0.16 | $0.24 | $1.60 | $0.26 | $0.29 |
Diluted EPS | $0.16 | $0.23 | $1.53 | $0.25 | $0.28 |
Basic Shares Outstanding | 134.9M | 131.8M | 131.9M | 132.4M | 130.1M |
Diluted Shares Outstanding | 137.5M | 136.0M | 138.1M | 137.6M | 133.5M |